Welcome to our dedicated page for Travere Therapeutics SEC filings (Ticker: TVTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Travere Therapeutics, Inc. filings document a rare-disease biopharmaceutical issuer whose disclosures center on FILSPARI (sparsentan), operating results, FDA regulatory events, and public-company governance. Recent 8-K reports furnish quarterly and annual financial results and disclose regulatory events involving FILSPARI in focal segmental glomerulosclerosis and IgA nephropathy.
Proxy materials cover annual meeting voting, board matters, executive compensation, equity awards, and stockholder governance. The filing record also documents formal event reporting under the Exchange Act for product-regulatory updates and financial-condition disclosures.
Travere Therapeutics, Inc. (TVTX) is the issuer in a notice that officer William Rote intends to sell 112,850 shares of common stock through Morgan Stanley Smith Barney LLC, with an aggregate market value of $7,054,253.50, as of a proposed sale date of September 16, 2026 on NASDAQ.
The shares to be sold were acquired from the issuer on September 16, 2026 via an exercise of stock options paid in cash. The notice also reports that during the prior three months, a separate Rule 10b5-1 sales program for E. Rote involved the sale of 96,198 shares of common stock on September 15, 2026 for aggregate proceeds of $5,988,758.39.
Travere Therapeutics, Inc. (TVTX) officer Peter Heerma filed a notice of proposed sale of company stock under Rule 144. The notice covers 172,717 shares of common stock, to be sold through Morgan Stanley Smith Barney, with an indicated aggregate market value of $10,796,539.67 as of September 16, 2026. Travere reports 94,261,082 shares of common stock outstanding. The securities to be sold were acquired on September 16, 2026 through an exercise of stock options for cash. In the prior three months, a separate sale of 102,190 shares of common stock for $6,362,824.52 on September 15, 2026 is also listed for Heerma under a 10b5-1 plan.
Travere Therapeutics, Inc. (TVTX) is the issuer for a planned sale of its common stock reported on behalf of Eric Dube under Rule 144. The notice covers the potential sale of 195,841 shares of common stock on September 16, 2026, in connection with an exercise of stock options for cash.
The securities are held through Morgan Stanley Smith Barney LLC Executive Financial Services and are listed on NASDAQ. Over the prior three months, a separate Rule 10b5-1 transaction on September 15, 2026 involved 95,666 shares of common stock at an aggregate sale price of $5,955,801.63.
Travere Therapeutics, Inc. (TVTX) has a notice under Rule 144 indicating that officer Sandra Calvin may sell up to 5,375 shares of Travere common stock. The shares are associated with an exercise of stock options for cash and are to be sold through Morgan Stanley Smith Barney LLC Executive Financial Services, with an aggregate value of $353,621.25 as of September 15, 2026 on NASDAQ.
Travere Therapeutics, Inc. (TVTX) officer Christopher Cline filed a notice of proposed sale of Travere common stock under Rule 144. The filing contemplates the sale of up to 50,508 shares of common stock through Morgan Stanley Smith Barney LLC on or after September 15, 2026.
The shares to be sold include 20,000 shares related to an Exercise of Stock Options dated September 15, 2026 and 30,508 shares acquired from Restricted Stock Units granted May 9, 2020 and vesting through September 1, 2026. The notice also reports a prior sale of 642 shares on September 2, 2026.
Travere Therapeutics, Inc. (TVTX) has a notice of proposed sale of common stock filed under Rule 144 for officer Elizabeth Reed. The notice covers 39,576 shares of Travere common stock to be sold through Morgan Stanley Smith Barney, with an aggregate market value of $2,603,705.04 and based on 94,261,082 shares outstanding as of September 15, 2026. The shares consist of 37,500 shares underlying stock options expected to be exercised for cash on September 15, 2026 and 2,076 shares from performance stock units with a date of May 4, 2026.
Travere Therapeutics, Inc. (TVTX) received a notice that Eric Dube plans to sell shares of the company’s common stock under Rule 144. The notice covers up to 95,666 shares of common stock with an aggregate market value of $6,293,866.14 as of September 15, 2026.
The planned sale is to be effected through Morgan Stanley Smith Barney LLC Executive Financial Services on the NASDAQ market and is tied to the exercise of stock options for cash on September 15, 2026.
Travere Therapeutics, Inc. (TVTX) discloses that officer Peter Heerma has filed a notice to sell up to 102,190 shares of common stock under Rule 144 through Morgan Stanley Smith Barney LLC, with sales expected to begin on or about September 15, 2026 on NASDAQ.
The shares relate to equity compensation awards, including 77,190 shares from stock options exercisable for cash, and shares underlying restricted stock units and performance stock units that vested over the period from October 1, 2021 through January 31, 2025.
Travere Therapeutics, Inc. (TVTX) received a notice that officer William Rote plans to sell up to 96,198 shares of common stock under Rule 144 through Morgan Stanley Smith Barney LLC, with an approximate aggregate market value of $6,328,866.42. The planned sales are expected to occur on or about September 15, 2026 on NASDAQ. As context, 94,261,082 shares of common stock were outstanding, a baseline figure, not the amount being sold.
The shares to be sold were acquired via several equity compensation arrangements: 78,650 shares from the exercise of stock options, 9,128 shares from an employee stock purchase plan, and a total of 8,420 shares from restricted and performance stock units that vested between February 13, 2018 and January 31, 2024.
Travere Therapeutics, Inc. (TVTX) has an officer, Jula Inrig, filing a notice of proposed sale of common stock under Rule 144. The notice lists common shares to be sold through Morgan Stanley Smith Barney LLC on NASDAQ around September 15, 2026, with a quantity of 44,674 shares and an aggregate market value of $2,939,102.46, while the company reports 94,261,082 common shares outstanding.
The securities to be sold were acquired from the issuer through equity compensation, including stock options exercised for 32,395 shares on September 15, 2026, restricted stock units vesting for 7,662 shares on January 1, 2023, and performance stock units vesting for 4,617 shares on February 10, 2025. The notice states that the securities to be sold were acquired upon vesting of restricted stock units during the period from January 1, 2023 through January 31, 2025.